Cargando…
Analysis of the health product pipeline for poverty-related and neglected diseases using the Portfolio-to-Impact (P2I) modeling tool
Background: To estimate how much additional funding is needed for poverty-related and neglected disease (PRND) product development and to target new resources effectively, policymakers need updated information on the development pipeline and estimated costs to fill pipeline gaps. Methods: We previou...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000 Research Limited
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120931/ https://www.ncbi.nlm.nih.gov/pubmed/35634166 http://dx.doi.org/10.12688/f1000research.24015.1 |
_version_ | 1784711043972333568 |
---|---|
author | Bandara, Shashika Chapman, Nick Chowdhary, Vipul Doubell, Anna Hynen, Amelia Rugarabamu, George Gunn, Alexander Yamey, Gavin |
author_facet | Bandara, Shashika Chapman, Nick Chowdhary, Vipul Doubell, Anna Hynen, Amelia Rugarabamu, George Gunn, Alexander Yamey, Gavin |
author_sort | Bandara, Shashika |
collection | PubMed |
description | Background: To estimate how much additional funding is needed for poverty-related and neglected disease (PRND) product development and to target new resources effectively, policymakers need updated information on the development pipeline and estimated costs to fill pipeline gaps. Methods: We previously conducted a pipeline review to identify candidates for 35 neglected diseases as of August 31, 2017 (“2017 pipeline”). We used the Portfolio-to-Impact (P2I) tool to estimate costs to move these candidates through the pipeline, likely launches, and additional costs to develop “missing products.” We repeated this analysis, reviewing the pipeline to August 31, 2019 to get a time trend. We made a direct comparison based on the same 35 diseases (“2019 direct comparison pipeline”), then a comparison based on an expanded list of 45 diseases (“2019 complete pipeline”). Results: In the 2017 pipeline, 538 product candidates met inclusion criteria for input into the model; it would cost $16.3 billion (B) to move these through the pipeline, yielding 128 launches. In the 2019 direct comparison pipeline, we identified 690 candidates, an increase of 152 candidates from 2017; the largest increase was for Ebola. The direct comparison 2019 pipeline yields 196 launches, costing $19.9B. In the 2019 complete pipeline, there were 754 candidates, an increase of 216 candidates from 2017, of which 152 reflected pipeline changes and 64 reflected changes in scope. The complete pipeline 2019 yields 207 launches, costing $21.0B. There would still be 16 “missing products” based on the complete 2019 pipeline; it would cost $5.5B-$14.2B (depending on product complexity) to develop these products. Conclusion: The PRNDs product development pipeline has grown by over a quarter in two years. The number of expected new product launches based on the 2019 pipeline increased by half compared to 2017; the cost of advancing the pipeline increased by a quarter. |
format | Online Article Text |
id | pubmed-9120931 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | F1000 Research Limited |
record_format | MEDLINE/PubMed |
spelling | pubmed-91209312022-05-27 Analysis of the health product pipeline for poverty-related and neglected diseases using the Portfolio-to-Impact (P2I) modeling tool Bandara, Shashika Chapman, Nick Chowdhary, Vipul Doubell, Anna Hynen, Amelia Rugarabamu, George Gunn, Alexander Yamey, Gavin F1000Res Research Article Background: To estimate how much additional funding is needed for poverty-related and neglected disease (PRND) product development and to target new resources effectively, policymakers need updated information on the development pipeline and estimated costs to fill pipeline gaps. Methods: We previously conducted a pipeline review to identify candidates for 35 neglected diseases as of August 31, 2017 (“2017 pipeline”). We used the Portfolio-to-Impact (P2I) tool to estimate costs to move these candidates through the pipeline, likely launches, and additional costs to develop “missing products.” We repeated this analysis, reviewing the pipeline to August 31, 2019 to get a time trend. We made a direct comparison based on the same 35 diseases (“2019 direct comparison pipeline”), then a comparison based on an expanded list of 45 diseases (“2019 complete pipeline”). Results: In the 2017 pipeline, 538 product candidates met inclusion criteria for input into the model; it would cost $16.3 billion (B) to move these through the pipeline, yielding 128 launches. In the 2019 direct comparison pipeline, we identified 690 candidates, an increase of 152 candidates from 2017; the largest increase was for Ebola. The direct comparison 2019 pipeline yields 196 launches, costing $19.9B. In the 2019 complete pipeline, there were 754 candidates, an increase of 216 candidates from 2017, of which 152 reflected pipeline changes and 64 reflected changes in scope. The complete pipeline 2019 yields 207 launches, costing $21.0B. There would still be 16 “missing products” based on the complete 2019 pipeline; it would cost $5.5B-$14.2B (depending on product complexity) to develop these products. Conclusion: The PRNDs product development pipeline has grown by over a quarter in two years. The number of expected new product launches based on the 2019 pipeline increased by half compared to 2017; the cost of advancing the pipeline increased by a quarter. F1000 Research Limited 2020-05-21 /pmc/articles/PMC9120931/ /pubmed/35634166 http://dx.doi.org/10.12688/f1000research.24015.1 Text en Copyright: © 2020 Bandara S et al. https://creativecommons.org/licenses/by/3.0/igo/This is an open access article distributed under the terms of the Creative Commons Attribution IGO Licence. |
spellingShingle | Research Article Bandara, Shashika Chapman, Nick Chowdhary, Vipul Doubell, Anna Hynen, Amelia Rugarabamu, George Gunn, Alexander Yamey, Gavin Analysis of the health product pipeline for poverty-related and neglected diseases using the Portfolio-to-Impact (P2I) modeling tool |
title | Analysis of the health product pipeline for poverty-related and neglected diseases using the Portfolio-to-Impact (P2I) modeling tool |
title_full | Analysis of the health product pipeline for poverty-related and neglected diseases using the Portfolio-to-Impact (P2I) modeling tool |
title_fullStr | Analysis of the health product pipeline for poverty-related and neglected diseases using the Portfolio-to-Impact (P2I) modeling tool |
title_full_unstemmed | Analysis of the health product pipeline for poverty-related and neglected diseases using the Portfolio-to-Impact (P2I) modeling tool |
title_short | Analysis of the health product pipeline for poverty-related and neglected diseases using the Portfolio-to-Impact (P2I) modeling tool |
title_sort | analysis of the health product pipeline for poverty-related and neglected diseases using the portfolio-to-impact (p2i) modeling tool |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120931/ https://www.ncbi.nlm.nih.gov/pubmed/35634166 http://dx.doi.org/10.12688/f1000research.24015.1 |
work_keys_str_mv | AT bandarashashika analysisofthehealthproductpipelineforpovertyrelatedandneglecteddiseasesusingtheportfoliotoimpactp2imodelingtool AT chapmannick analysisofthehealthproductpipelineforpovertyrelatedandneglecteddiseasesusingtheportfoliotoimpactp2imodelingtool AT chowdharyvipul analysisofthehealthproductpipelineforpovertyrelatedandneglecteddiseasesusingtheportfoliotoimpactp2imodelingtool AT doubellanna analysisofthehealthproductpipelineforpovertyrelatedandneglecteddiseasesusingtheportfoliotoimpactp2imodelingtool AT hynenamelia analysisofthehealthproductpipelineforpovertyrelatedandneglecteddiseasesusingtheportfoliotoimpactp2imodelingtool AT rugarabamugeorge analysisofthehealthproductpipelineforpovertyrelatedandneglecteddiseasesusingtheportfoliotoimpactp2imodelingtool AT gunnalexander analysisofthehealthproductpipelineforpovertyrelatedandneglecteddiseasesusingtheportfoliotoimpactp2imodelingtool AT yameygavin analysisofthehealthproductpipelineforpovertyrelatedandneglecteddiseasesusingtheportfoliotoimpactp2imodelingtool |